Table 3 Overall investigator-assessed response rate to bevacizumab-based therapy according to patient age
Response, n (%) | Age <70 years (n = 1297) | Age ≥70 years (n = 480) | Age <75 years (n = 1571) | Age ≥75 years (n = 206) |
|---|---|---|---|---|
Complete response | 104 (8) | 34 (7) | 139 (9) | 17 (8) |
Partial response | 645 (50) | 209 (44) | 734 (47) | 77 (37) |
Stable disease | 348 (27) | 139 (29) | 461 (29) | 72 (35) |
Progressive disease | 96 (7) | 45 (9) | 115 (7) | 17 (8) |
Not evaluable | 41 (3) | 12 (3) | 122 (8) | 23 (11) |